Embolotherapy Global Market Report 2025

The embolotherapy market size has grown strongly in recent years. It will grow from $4.44 billion in 2024 to $4.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising demand for embolotherapy in treatment, the increasing incidence of cancer and peripheral vascular diseases, growing healthcare expenditure, and higher investment in research.

The embolotherapy market size is expected to see strong growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth during the forecast period can be attributed to rising disposable income, the increasing prevalence of chronic diseases, the growing adoption of embolotherapy in reproductive health, the rising number of chemoembolization procedures, and the increasing incidence of liver cancer. Key trends in the forecast period include advancements in cutting-edge technologies, the development of digital and analog devices, the use of insertable cardiac monitors, innovations in embolotherapy techniques, and strategic collaborations.

The growing preference for minimally invasive procedures is expected to drive the expansion of the embolotherapy market. Minimally invasive procedures involve cosmetic and medical treatments that require little to no surgical intervention, offering benefits such as reduced recovery time, less pain, smaller scars, lower risks of complications, and improved precision due to technological advancements. Embolotherapy supports minimally invasive procedures by selectively blocking blood flow to targeted vessels, reducing bleeding, treating tumors, and managing vascular abnormalities with greater accuracy and fewer complications. For instance, in September 2023, the American Society of Plastic Surgeons, a US-based non-profit organization, reported that cosmetic minimally invasive procedures increased by 7% in 2023, reaching 25,442,640 treatments, up from 23,672,269 in 2022. As a result, the increasing preference for minimally invasive procedures is fueling the growth of the embolotherapy market.

Leading companies in the embolotherapy market are focusing on developing innovative solutions, such as absorbable embolic systems, to enhance patient outcomes and expand treatment options. Absorbable embolic systems are bioresorbable materials used in embolization procedures to block blood flow to targeted tissues, such as tumors or aneurysms, while gradually degrading within the body over time. For example, in January 2025, Instylla Inc., a US-based medical equipment manufacturer, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Tembo embolic system, a bioresorbable embolization agent made of irregularly shaped, dry-gelatin particles sized between 85 and 255 µm. The system is designed to embolize hypervascular tumors and occlude blood vessels in the peripheral vasculature. According to Instylla, Tembo offers advantages such as easy preparation, high visibility, and the ability to densely pack treated vessels, potentially improving upon existing permanent embolic solutions.

In November 2024, Merit Medical Systems Inc., a US-based healthcare technology company, acquired the Lead Management Portfolio from Cook Medical for approximately $210 million. This acquisition aims to strengthen Merit Medical Systems' electrophysiology (EP) and cardiac rhythm management (CRM) business by expanding its product portfolio and market reach. Cook Medical LLC is a US-based medical device company specializing in embolization coils.

Major players in the embolotherapy market are Boston Scientific Corporation, Terumo Medical Corporation, Medtronic PLC, Johnson And Johnson, Stryker Corporation, Sirtex Medical, Abbott Laboratories, Acandis GmbH, Balt Group LLC, Penumbra Inc, Merit Medical Systems, Kaneka Corporation, Meril Life Sciences Pvt. Ltd., Shape Memory Medical Inc, Guerbet, IMBiotechnologies Ltd, Cardiva, Rapid Medical, Emboline Inc, Microport Scientific, Inari Medical, Instylla Inc, Embolx Inc, GE Healthcare, Lepu Medical Technology Co Ltd, WEGO HEALTHCARE (SHENZHEN) CO., LTD, Achieva Medical Inc, Varian Medical Syatems Inc.

North America was the largest region in the embolotherapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in embolotherapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the embolotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Embolotherapy is a minimally invasive medical procedure that involves deliberately blocking blood vessels to treat various conditions. This is achieved by injecting embolic agents such as microspheres, coils, gels, or liquid embolics into targeted blood vessels, cutting off the blood supply to abnormal tissues or structures. As a highly targeted alternative to traditional surgery, embolotherapy is typically performed by interventional radiologists, offering improved patient outcomes with minimal recovery time.

The primary product types used in embolotherapy include embolization coils, embolic agents, detachable balloons, embolic plug systems, and support devices. Embolization coils are small, flexible devices designed to block blood flow in targeted vessels, treating conditions such as aneurysms, tumors, and vascular malformations. These products are applied in various medical fields, including oncology, peripheral vascular diseases, urology and nephrology, neurology, and gastrointestinal (GIT) disorders. Embolotherapy procedures include transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). The key end users of embolotherapy products include ambulatory surgical centers, hospitals, clinics, and other healthcare providers.

The embolotherapy market research report is one of a series of new reports that provides embolotherapy market statistics, including the embolotherapy industry global market size, regional shares, competitors with the embolotherapy market share, detailed embolotherapy market segments, market trends, and opportunities, and any further data you may need to thrive in the embolotherapy industry. This embolotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The embolotherapy market consists of revenues earned by entities by providing services such as catheter-based embolization, flow diversion therapy, tumor embolization, uterine fibroid embolization, and endovenous embolization for varicose veins. The market value includes the value of related goods sold by the service provider or included within the service offering. The embolotherapy market also includes sales of microcatheters, liquid embolic agents, particle embolic agents, balloon occlusion devices, and flow diverters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.